Eli Radiopharma raises $60m to accelerate cancer and neurological treatments

Chinese biotechnology company Eli Radiopharma has raised approximately $60m in Series A funding led by Huagai Capital and Bayland Capital. The investment will support the development of radiopharmaceutical treatments for cancer and neurological diseases, including preclinical research and early clinical development. HPC could introduce pharmaceutical manufacturers, clinical research organisations, specialist laboratories, medical equipment suppliers and international healthcare investors interested in China's growing biotechnology market.

If you are interested to enquire further, please fill in the form below with your details and one of our consultants will contact you shortly.